Benefits Outweigh Risks Associated With Newborn Screening for Disorder
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Benefits Outweigh Risks Associated With Newborn Screening for Disorder

ANN ARBOR, Mich -- February 1, 2010 -- Newborn screening for medium chain acyl-CoA dehydrogenase deficiency (MCADD) could lead to false positives -- adding stress to parents, costing money, and possibly subjecting a baby to unnecessary follow-up treatment and dietary restrictions.

However, the benefits of diagnosing these children early and preventing the risk of mental retardation, disability or death outweigh the costs of a false positive, according to study published today in the February issue of the journal Pediatrics.

“Published studies of expanded newborn screening in a United States setting have resulted in favourable cost-effective ratios for screening for this illness but did not include primary data for quality of life effects for a false positive screen,” said lead author Lisa Prosser, PhD, Division of General Pediatrics, University of Michigan Health System, Ann Arbor, Michigan.

“Our results show that newborn screening remains cost-effective after accounting for the measured loss in quality of life associated with a false positive screen.”

While MCADD patients are usually healthy, repeated episodes of metabolic crisis can cause permanent brain damage. This may result in learning problems and mental retardation.

Researchers used a computer model that took into account costs of screening, including the initial screen test, parent time and medical costs of follow-up testing, treatment, and the quality of life implications of having dietary restrictions.

They found that screening requires substantial investment of resources but in exchange for important health benefits. ”The cost-effectiveness of newborn screening for MCADD is comparable to cost-effectiveness for other childhood interventions, such as vaccinations,” said Dr. Prosser.

“Newborn screening for MCADD remains cost-effective even when the loss in quality of life associated with false positives or dietary treatments are taken into account.”

SOURCE: University of Michigan Health System

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities